A Review of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, for Moderate-to-Severe Plaque Psoriasis.
Skin Therapy Lett
; 21(6): 1-6, 2016 Nov.
Article
em En
| MEDLINE
| ID: mdl-27825174
ABSTRACT
Psoriasis is a multifactorial chronic skin disease that can have significant detrimental effects on patients' physical, mental, antibodypsychosocial wellbeing. Patients often suffer from a decreased quality of life along with numerous comorbidities. Recent advances in our understanding of the innate and adaptive immune systems have led to the identification of interleukin (IL)-17 as a key pro-inflammatory mediator in psoriasis. This knowledge has in turn led to the development of newer biologic agents that have been shown to be more effective than traditional therapies. In this article, we review phase 1-3 clinical trials of the anti-IL-17 monoclonal antibody, ixekizumab, for treatment of moderate-to-severe plaque psoriasis.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Psoríase
/
Interleucina-17
/
Fármacos Dermatológicos
/
Anticorpos Monoclonais Humanizados
Limite:
Humans
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article